Desethylhydroxychloroquine for the treatment of diseases associated with inflammation
Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
1. A method of treating an inflammatory disease comprising: administering to an individual in need thereof who is at increased risk of retinal toxicity, with one or more daily doses of a pharmaceutical composition comprising desethylhydroxychloroquine (DHCQ) or pharmaceutically acceptable salts or esters thereof, wherein the daily dose is 400-600 mg/day of DHCQ or pharmaceutically acceptable salts or esters thereof.
2. The method of claim 1 , wherein the daily amount of DHCQ or pharmaceutically acceptable salts or esters thereof administered to the individual for the first 1 to 16 weeks is higher than the daily amount of DHCQ or pharmaceutically acceptable salts or esters thereof administered subsequently.
3. The method of claim 1 , wherein the inflammatory disease is systemic lupus erythematosus.
4. The method of claim 1 , wherein the individual exhibits symptoms of the early stages of the inflammatory disease.
5. The method of claim 1 , wherein the individual is asymptomatic and identified as being at increased risk for developing the inflammatory disease.
6. The method of claim 1 , wherein said administering is carried out for a period of at least 10 years.
7. The method of claim 1 , wherein there is reduced screening for retinal toxicity compared to treatment with HCQ.
8. The method of claim 7 , wherein screening starts after 10 years of said administration.
9. A method of inhibiting the development of an inflammatory disease in a mammal comprising:
(i) identifying an individual exhibiting early stages of an inflammatory disease,
(ii) measuring a marker of inflammation in the individual,
(iii) comparing the level of the marker of inflammation measured in the individual with the reference range of the normal level of the biomarker of inflammation measured in healthy individuals to determine if the individual exhibits increased inflammation,
(iv) if the individual shows increased inflammation, treating the individual with one or more daily doses of a pharmaceutical composition comprising DHCQ or pharmaceutically acceptable salts or esters thereof, wherein the daily dose is 400-600 mg/day of DHCQ or pharmaceutically acceptable salts or esters thereof.
10. The method of claim 9 wherein the marker of inflammation is measured by imaging.
11. The method of claim 9 wherein the marker of inflammation is a molecular marker.
12. The method of claim 9 wherein the marker of inflammation is a clinical marker.
13. The method of claim 9 , wherein the inflammatory disease is type II diabetes.
14. The method of claim 9 , wherein the inflammatory disease is non-alcoholic steatohepatitis.
15. The method of claim 1 , further comprising initiating retinal toxicity screening of the individual beginning no earlier than about 5 years after initiating said treating.
16. The method of claim 15 , wherein said retinal toxicity screening is carried out at intervals of about 2 years.
17. The method of claim 9 , further comprising initiating retinal toxicity screening of the individual beginning no earlier than about 5 years after initiating said treating.
18. The method of claim 17 , wherein said retinal toxicity screening is carried out at intervals of about 2 years.
19. The method of claim 9 , wherein there is reduced screening for retinal toxicity compared to treatment with HCQ.
20. The method of claim 9 , wherein said individual does not require screening for retinal toxicity after initiating said treating.
21. The method of claim 1 , wherein the inflammatory disease is rheumatoid arthritis.
22. The method of claim 1 , wherein the inflammatory disease is a degenerative disease selected from the group consisting of osteoarthritis, Alzheimer's disease, and macular degeneration.
23. The method of claim 1 , wherein the inflammatory disease is a metabolic disease selected from the group consisting of type II diabetes, atherosclerosis and non-alcoholic steatohepatitis.
24. The method of claim 1 , wherein the inflammatory disease is a chronic infection.
25. The method of claim 23 , wherein the inflammatory disease is type II diabetes.
26. The method of claim 23 , wherein the inflammatory disease is non-alcoholic steatohepatitis.
27. The method of claim 24 , wherein the chronic infection is HIV.
28. The method of claim 1 , wherein after 10 years of said administration, the individual is substantially without symptoms of retinal toxicity.
29. The method of claim 1 , wherein said individual does not require screening for retinal toxicity after initiating said treating.
30. The method of claim 10 , wherein the imaging is selected from the group consisting of magnetic resonance imaging, ultrasound imaging, and computed tomography.
31. The method of claim 11 wherein the molecular marker is selected from the group consisting of a c-reactive protein, a cytokine, an antibody, a DNA sequence, an RNA sequence, and insulin resistance.
32. The method of claim 12 wherein the clinical marker is a finding of swelling on physical examination.